Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2

By sjmartinez • March 6, 2023

Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00020-7. doi: 10.1016/j.cllc.2023.02.002. Epub ahead of print. PMID: 36872181.

Tags: Adjuvant, Early-stage, Hematology/Oncology, Publications, Resectable, targeted therapy, Tyrosine kinase inhibitor

Structural Evaluations of a Selective Human STINGA230 Agonist and Its Use in Macrophage Immunotherapies

Tang Z, Zhao J, Li Y, Tomer S, Selvaraju M, Tien N, Sun D, Johnson DK, Zhen A, Li P, Wang J. Structural Evaluations of[...]

Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method

Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, Li Z, Yu Y, Dunn[...]

Cracking the Genomic Code of CDK4/6 Inhibitor Resistance

Wander SA, Bardia A. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance. Clin Cancer Res. 2024 May 15;30(10):2008-2010. doi: 10.1158/1078-0432.CCR-23-3413. PMID: 38319645.